Stifel Downgrades Bolt Biotherapeutics to Hold, Lowers Price Target to $1.5
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Stephen Willey has downgraded Bolt Biotherapeutics (NASDAQ:BOLT) from Buy to Hold and lowered the price target from $6 to $1.5.
May 15, 2024 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics from Buy to Hold and significantly lowered the price target from $6 to $1.5.
The downgrade from Buy to Hold and the significant reduction in the price target from $6 to $1.5 by a reputable analyst is likely to negatively impact investor sentiment and the stock price of Bolt Biotherapeutics in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100